MicroRNA binding site polymorphisms in immunoinflammatory genes have been implicated as candidate biomarkers for prediction of complex human diseases. However, the roles of microRNA binding site polymorphisms in stroke onset and prognosis remain unclear. Thus, for the first time, five potential functional polymorphisms in immunoinflammatory genes (CXCR2 rs1126579, TLR4 rs11536889, ADIPOR2 rs12342, MMP-2 rs7201 and MMP-9 rs1056628) were genotyped in 657 patients with ischemic stroke. These five polymorphisms were not related with age onset of ischemic stroke. However, we found that ADIPOR2 rs12342 was significantly associated with a decreased recurrence risk, especially for the patients with small-vessel disease. Moreover, by using multivariate Cox regression, the variant genotype GG/GA of rs12342 was observed as an independent protective factor for stroke recurrence, even after Bonferroni correction. In addition, after the addition of rs12342 in the model with clinical factors, the new model showed the improved discriminatory ability to predict stroke recurrence. In short, our results suggested that ADIPOR2 rs12342 may be a novel genetic biomarker and therapeutic target for ischemic stroke recurrence. Further studies are required to replicate our findings and clarify the potential biological mechanism.

免疫炎症基因中的MicroRNA结合位点多态性已被认为是预测复杂人类疾病的候选生物标记。然而，microRNA结合位点多态性在中风发作和预后中的作用仍不清楚。因此，首次对657名缺血性卒中患者的免疫炎症基因（CXCR2 rs1126579，TLR4 rs11536889，ADIPOR2 rs12342，MMP-2 rs7201和MMP-9 rs1056628）的五个潜在功能性多态性进行了基因分型。这五个多态性与缺血性中风的年龄发作无关。但是，我们发现ADIPOR2 rs12342与降低的复发风险显着相关，尤其是对于患有小血管疾病的患者。而且，通过使用多元Cox回归，甚至在Bonferroni校正后，rs12342的GG / GA变异基因型仍被视为卒中复发的独立保护因子。此外，在具有临床因素的模型中添加rs12342后，新模型显示出更好的预测中风复发的鉴别能力。简而言之，我们的结果表明ADIPOR2 rs12342可能是缺血性中风复发的新型遗传生物标志物和治疗靶标。需要进一步的研究来复制我们的发现并阐明潜在的生物学机制。我们的结果表明，ADIPOR2 rs12342可能是缺血性中风复发的新型遗传生物标志物和治疗靶标。需要进一步的研究来复制我们的发现并阐明潜在的生物学机制。我们的结果表明，ADIPOR2 rs12342可能是缺血性中风复发的新型遗传生物标志物和治疗靶标。需要进一步的研究来复制我们的发现并阐明潜在的生物学机制。